Phaseline

Companies › Akebia Therapeutics

Akebia Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Genitourinary, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Praliciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Focal Segmental GlomerulosclerosisJun 2027
ADX-097–Phase 2IgA NephropathyFeb 2028
AKB-9090–Phase 1Healthy VolunteersDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07429006AKB-9090Phase 1Healthy VolunteersOtherDec 2026
NCT07268638PraliciguatPhase 2Focal Segmental GlomerulosclerosisGenitourinaryJun 2027
NCT06419205ADX-097Phase 2IgA NephropathyGenitourinaryFeb 2028

From the company's SEC filings

Cash of $159m on 2026-09-30; operating cash outflow about $21m a year; runway about 93 months at that burn, to Jun 2034; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

GUCY1B1 (1) GUCY1A2 (1) GUCY1A1 (1)

Companies with the same targets

Merck & Co. (MSD) Kardigan Bayer Pulmovant Coherus Oncology

Companies built like this

Jade Biosciences Clinique Ovo Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Neurocrine Switzerland Shanghai Bao Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.